Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026

Arcturus Therapeutics Holdings Inc.

Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.
Regained global rights to KOSTAIVE and infectious disease portfolio from CSL Seqirus; received $12M cash and $16M in released liabilities.
ARCT-032 (CF) Phase 2 enrollment on schedule; decision to proceed to Phase 3 expected Q4 2026; Thermo Fisher collaboration for Phase 3.
ARCT-810 (OTC deficiency) Phase 2 enrollment and dosing completed; data and regulatory plan expected Q3 2026.
Cash and cash equivalents $191.5M as of June 30, 2026; cash runway over 2.5 years through year end 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.